Assess whether RWE can replace or only supplement an RCT (e2fc65)

Situation

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study has one working extract — phase-3 protocol with endpoint-sensitivity issues — after a payer demanding RWE the protocol cannot generate. Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study has phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate. If that extract cannot support RWE can replace or, the honest Pharma & Life Sciences Pharmacovigilance output is hold.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• Clinical-development physician can defend RWE can replace from phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate in a Pharma & Life Sciences challenge.
• Clinical-development physician cannot defend RWE can replace from phase-3 protocol with endpoint-sensitivity issues; Only supplement an RCT is what the extract actually supports after a payer demanding RWE the protocol cannot generate.
• A payer demanding RWE the protocol cannot generate never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close RWE can replace or.
• Two facts in phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate conflict for clinical-development physician; hold this Pharmacovigilance file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a payer demanding RWE the protocol cannot generate and write the one fact that would move RWE can replace or for clinical-development physician.

Recommendation